- Home
- FCFS vs IONS Comparison
FCFS vs IONS Comparison
Compare FCFS & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCFS
- IONS
- Stock Information
- Founded
- FCFS 1988
- IONS 1989
- Country
- FCFS United States
- IONS United States
- Employees
- FCFS N/A
- IONS N/A
- Industry
- FCFS Other Specialty Stores
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- FCFS Consumer Discretionary
- IONS Health Care
- Exchange
- FCFS Nasdaq
- IONS Nasdaq
- Market Cap
- FCFS 5.9B
- IONS 5.4B
- IPO Year
- FCFS 1991
- IONS 1991
- Fundamental
- Price
- FCFS $127.91
- IONS $33.51
- Analyst Decision
- FCFS Buy
- IONS Buy
- Analyst Count
- FCFS 3
- IONS 18
- Target Price
- FCFS $133.50
- IONS $57.41
- AVG Volume (30 Days)
- FCFS 290.5K
- IONS 1.5M
- Earning Date
- FCFS 07-24-2025
- IONS 04-30-2025
- Dividend Yield
- FCFS 1.19%
- IONS N/A
- EPS Growth
- FCFS 21.73
- IONS N/A
- EPS
- FCFS 6.25
- IONS N/A
- Revenue
- FCFS $3,388,567,000.00
- IONS $717,253,000.00
- Revenue This Year
- FCFS $2.67
- IONS $7.14
- Revenue Next Year
- FCFS $5.58
- IONS $18.89
- P/E Ratio
- FCFS $20.47
- IONS N/A
- Revenue Growth
- FCFS 5.06
- IONS N/A
- 52 Week Low
- FCFS $100.24
- IONS $23.95
- 52 Week High
- FCFS $135.57
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- FCFS 50.75
- IONS 56.80
- Support Level
- FCFS $126.22
- IONS $32.00
- Resistance Level
- FCFS $128.99
- IONS $33.65
- Average True Range (ATR)
- FCFS 2.49
- IONS 1.08
- MACD
- FCFS -0.58
- IONS -0.10
- Stochastic Oscillator
- FCFS 35.91
- IONS 55.72
About FCFS FirstCash Holdings Inc.
FirstCash Holdings Inc operates pawn stores in the United States and Latin America. Its primary business involves making small loans secured by personal property. The the company has three reportable segments: U.S. pawn; Latin America pawn; and Retail POS payment solutions (AFF). It derives majority revenue from U.S. Pawn segment. These pawn loans give the borrower the option of either repaying the loans with interest or forfeiting the property without further penalty. Geographically operates in USA, Mexico, Latin America, with maximum revenue from USA.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.